{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Cartistem",
            "NStudiesAvail": 430108,
            "NStudiesFound": 6,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 6,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "evaluate the efficacy of adding allogenic umbilical cord blood-derived stem cell product(Cartistem\u00ae) by 100-mm VAS(Visual Analogue Scale)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Baseline, Week 4, Week 8, Week 12, Week 24, Week 48"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02338375"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [
                              "May 25, 2021"
                        ],
                        "ResultsFirstSubmitQCDate": [
                              "July 11, 2021"
                        ],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.\n\n100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain.",
                              "The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs. The possible score ranges from 0 to 100, where 100 = no symptoms or disability. Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (\u226464). Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.",
                              "The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL). Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from \"never/not at all\" to \"always/extremely.\" The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems. Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration. The outcome was presented with the post-operative change amount at Month 24 from the baseline.",
                              "Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion. The outcome was presented with the post-operative change amount at Month 24 from the baseline."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "VAS",
                              "Lysholm Score",
                              "KOOS Score",
                              "IKDC Score"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "24 months",
                              "24 months",
                              "24 months",
                              "24 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Study to Compare the Efficacy and Safety of Cartistem\u00ae and Microfracture in Patients With Knee Articular Cartilage Injury or Defect"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://clinicaltrials.gov/ct2/show/NCT01041001?term=cartistem&rank=2"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01733186"
                        ]
                  },
                  {
                        "Rank": 3,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Degree of improvement in the grade of joint pain measured on a 100-mm VAS (Visual Analogue Scale)",
                              "Grade of cartilage regeneration in patients who agreed to a biopsy during arthroscopy at week 48",
                              "Changes in WOMAC scores",
                              "Changes in IKDC Subjective Score",
                              "ICRS scores"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Week 0, 2, 4, 8, 12, 24, 36 and 48",
                              "Week 48",
                              "Week 0, 2,4,8,12,24,36 and 48",
                              "Week 0, 2, 4, 8, 12, 24, 36 and 48",
                              "Week 48"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01041001"
                        ]
                  },
                  {
                        "Rank": 4,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Systemic and local adverse events especially attributable to the implanted cells will be assessed.\n\nGeneral physical examinations: vital signs, blood tests\nPhysical assessments of the knee: swelling, tenderness, pain, range of motion\nTumor formation at the implantation site: radiological evaluation using MRI(T1(dGEMRIC)and T2 mapping)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Number of subjects with adverse events"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "36 months, 48 months, and 60 months"
                        ],
                        "SeeAlsoLinkLabel": [
                              "Study to Compare the Efficacy and Safety of Cartistem\u00ae and Microfracture in Patients With Knee Articular Cartilage Injury or Defect"
                        ],
                        "SeeAlsoLinkURL": [
                              "http://clinicaltrials.gov/ct2/show/NCT01041001?term=cartistem&rank=1"
                        ],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT01626677"
                        ]
                  },
                  {
                        "Rank": 5,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [
                              "Arthroscopic grading of graft",
                              "Telos stress X-ray",
                              "KT-2000",
                              "clinical knee scoring",
                              "Instability assessing with physical examination",
                              "Tunnel enlargement after anterior cruciate ligament reconstruction"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "48 week after surgery",
                              "Changes at 12 week, 24 week, 48 week after surgery",
                              "Changes at 12 week, 24 week, 48 week after surgery",
                              "Changes at 12 week, 24 week, 48 week after surgery",
                              "Changes at 12 week, 24 week, 48 week after surgery",
                              "Changes at 12 week, 24 week, 48 week after surgery"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT02755376"
                        ]
                  },
                  {
                        "Rank": 6,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "The grades range from 1(normal) to 4 (severely abnormal) where lower grades indicate more complete repair",
                              "Changes in MOCART(Magnetic resonance Observation of Cartilage Repair Tissue) score\n\n: MOCART score is a 9-part and 29-item scoring system, also resulting in a find cartilage repair tissue score between 0 and 100 points. 100 points represent the best imaginable score",
                              ": FAOS consists in 42 items that cover 5 dimensions (symptoms, pain, activities of daily living, sport and recreation activities, and quality of life. Raw scores of each sub-scales results of the sum of each items. A normalized score (100 indicationg no symptoms and 0 indicating extreame sysmptoms) is calculated for each subscale",
                              ": AOFAS consists in 9 items that can be divided into 3 sub-scales (pain, function and alignment). 100 points of 1 to 100 represent no symptoms or impairments",
                              ": Tegner activity represents the highest level of activity on scale of 0 to 10 that you are able to participate in currently . The higher values represent a better outcome",
                              ": SF-36 comprises 36 items divided into two components of physical health and mental health. Higher scores between 0 and 100 represent better health status",
                              "VAS represents higher scores mean higher pain\n0 mm (no pain) and 100 mm (worst pain)"
                        ],
                        "SecondaryOutcomeMeasure": [
                              "ICRS-Cartilage Repair Assessment Overall Grade",
                              "Improvement degree of Cartilage Repair by MRI",
                              "Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)",
                              "Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)",
                              "Degree of Functional improvement in Tegner activity score",
                              "Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)",
                              "Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "Week 48",
                              "Week 0 and 48",
                              "Week 0, 24 and 48",
                              "Week 0, 24 and 48",
                              "Week 0, 24 and 48",
                              "Week 0, 24 and 48",
                              "Week 0, 24 and 48"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04310215"
                        ]
                  }
            ]
      }
}